Displaying drugs 11101 - 11125 of 11622 in total
Reposal
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Experimental
Matched Description: … Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and …
Elenbecestat
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Investigational
Matched Description: … Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy …
Giripladib
Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Investigational
Matched Description: … Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of …
CYNK-001
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
Matched Description: … CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental …
Birtamimab
Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Investigational
Matched Description: … Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global …
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
Matched Description: … IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B …
Reloxiliase
Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.
Investigational
Matched Description: … Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme …
Tosedostat
Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others.
Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models...
Investigational
Matched Description: … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and …
PPL-100
Investigational
Metiamide
Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Experimental
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
Matched Description: … KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for …
Solabegron
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
CHIR-124
CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Experimental
Matched Description: … CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in …
Delpazolid
Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study).
Investigational
Matched Description: … Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized …
Tiazofurine
Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase .
Experimental
Matched Description: … Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- …
2-fluorofucose
2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Investigational
Matched Description: … 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients …
Dinalbuphine sebacate
Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).
Investigational
Matched Description: … Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular …
Recombinant human plasma gelsolin
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Investigational
Matched Description: … Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds …
Ifidancitinib
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
Investigational
Matched Description: … Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution …
Emprumapimod
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
SPL23-2
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Matched Description: … SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a …
Horse chestnut
Horse chestnut is a flowering plant commonly referred to as Aesculus hippocastanum. Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions. These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract...
Experimental
Matched Description: … Horse chestnut is a flowering plant commonly referred to as *Aesculus hippocastanum*. ... Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
Displaying drugs 11101 - 11125 of 11622 in total